Causal Role of Immune Cells in Bipolar Disorder: a Mendelian Randomization Study

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2024 Sep 2

PMID 39220183

Authors

Mengxuan Wang

Shuo Wang

Guoshan Yuan

Mingzhou Gao

Xiyan Zhao

Zhenhan Chu

Dongmei Gao

Affiliations

Soon will be listed here.

Abstract

Background: The understanding of the immunological mechanisms underlying bipolar disorder (BD) has enhanced in recent years due to the extensive use of high-density genetic markers for genotyping and advancements in genome-wide association studies (GWAS). However, studies on the relationship between immune cells and the risk of BD remain limited, necessitating further investigation.

Methods: Bidirectional two-sample Mendelian Randomization (MR) analysis was employed to investigate the causal association between immune cell morphologies and bipolar disorder. Immune cell traits were collected from a research cohort in Sardinia, whereas the GWAS summary statistics for BD were obtained from the Psychiatric Genomics Consortium. Sensitivity analyses were conducted, and the combination of MR-Egger and MR-Presso was used to assess horizontal pleiotropy. Cochran's Q test was employed to evaluate heterogeneity, and the results were adjusted for false discovery rate (FDR).

Results: The study identified six immune cell phenotypes significantly associated with BD incidence (< 0.01). These phenotypes include IgD- CD27- %lymphocyte, CD33br HLA DR+ CD14- AC, CD8 on CD28+ CD45RA+ CD8br, CD33br HLA DR+ AC, CD14 on CD14+ CD16+ monocyte, and HVEM on CD45RA- CD4+. After adjusting the FDR to 0.2, two immune cell phenotypes remained statistically significant: IgD-CD27-% lymphocyte (OR=1.099, 95% CI: 1.051-1.149, = 3.51E-05, FDR=0.026) and CD33br HLA DR+ CD14-AC (OR=0.981, 95% CI: 0.971-0.991, = 2.17E-04, FDR=0.079). In the reverse MR analysis, BD significantly impacted the phenotypes of four monocytes (< 0.01), including CD64 on CD14+ CD16+ monocyte, CD64 on monocyte, CX3CR1 on CD14- CD16-, CD64 on CD14+ CD16- monocyte. However, after applying the FDR correction (FDR < 0.2), no statistically significant results were observed.

Conclusions: This MR investigation reveals associations between immune cell phenotypes, bipolar disorder, and genetics, providing novel perspectives on prospective therapeutic targets for bipolar disorder.

References

Corsi-Zuelli F, Deakin B, Haruo Fernandes de Lima M, Qureshi O, Barnes N, Upthegrove R . T regulatory cells as a potential therapeutic target in psychosis? Current challenges and future perspectives. Brain Behav Immun Health. 2021; 17:100330. PMC: 7611834. DOI: 10.1016/j.bbih.2021.100330. View

Wei Y, Feng J, Ma J, Chen D, Chen J . Neutrophil/lymphocyte, platelet/lymphocyte and monocyte/lymphocyte ratios in patients with affective disorders. J Affect Disord. 2022; 309:221-228. DOI: 10.1016/j.jad.2022.04.092. View

Gao K, Ayati M, Koyuturk M, Calabrese J, Ganocy S, Kaye N . Protein Biomarkers in Monocytes and CD4 Lymphocytes for Predicting Lithium Treatment Response of Bipolar Disorder: a Feasibility Study with Tyramine-Based Signal-Amplified Flow Cytometry. Psychopharmacol Bull. 2022; 52(1):8-35. PMC: 8896753. View

Sole B, Jimenez E, Torrent C, Reinares M, Bonnin C, Torres I . Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies. Int J Neuropsychopharmacol. 2017; 20(8):670-680. PMC: 5570032. DOI: 10.1093/ijnp/pyx032. View

Modabbernia A, Taslimi S, Brietzke E, Ashrafi M . Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013; 74(1):15-25. DOI: 10.1016/j.biopsych.2013.01.007. View

Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J . A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017; 36(11):1783-1802. PMC: 5434863. DOI: 10.1002/sim.7221. View

Wu T, Lee C, Wu B, Sun H, Chang C, Chen C . Immunophenotypes associated with bipolar disorder and lithium treatment. Sci Rep. 2019; 9(1):17453. PMC: 6877517. DOI: 10.1038/s41598-019-53745-7. View

Engh J, Ueland T, Agartz I, Andreou D, Aukrust P, Boye B . Plasma Levels of the Cytokines B Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) in Schizophrenia, Bipolar, and Major Depressive Disorder: A Cross Sectional, Multisite Study. Schizophr Bull. 2021; 48(1):37-46. PMC: 8781325. DOI: 10.1093/schbul/sbab106. View

Brietzke E, Rosa A, Pedrini M, Noto M, Kapczinski F, Scott J . Challenges and developments in research of the early stages of bipolar disorder. Braz J Psychiatry. 2016; 38(4):329-337. PMC: 7111347. DOI: 10.1590/1516-4446-2016-1975. View

10.

Qiu R, Zhou L, Ma Y, Zhou L, Liang T, Shi L . Regulatory T Cell Plasticity and Stability and Autoimmune Diseases. Clin Rev Allergy Immunol. 2018; 58(1):52-70. DOI: 10.1007/s12016-018-8721-0. View

11.

Zhao N, Topolski N, Tusconi M, Salarda E, Busby C, Lima C . Blood-brain barrier dysfunction in bipolar disorder: Molecular mechanisms and clinical implications. Brain Behav Immun Health. 2022; 21:100441. PMC: 8924633. DOI: 10.1016/j.bbih.2022.100441. View

12.

North H, Weissleder C, Fullerton J, Sager R, Webster M, Weickert C . A schizophrenia subgroup with elevated inflammation displays reduced microglia, increased peripheral immune cell and altered neurogenesis marker gene expression in the subependymal zone. Transl Psychiatry. 2021; 11(1):635. PMC: 8674325. DOI: 10.1038/s41398-021-01742-8. View

13.

Goldsmith D, Bekhbat M, Mehta N, Felger J . Inflammation-Related Functional and Structural Dysconnectivity as a Pathway to Psychopathology. Biol Psychiatry. 2023; 93(5):405-418. PMC: 9895884. DOI: 10.1016/j.biopsych.2022.11.003. View

14.

Morgan L, Rollins B, Sequeira A, Byerley W, DeLisi L, Schatzberg A . Quantitative Trait Locus and Brain Expression of HLA-DPA1 Offers Evidence of Shared Immune Alterations in Psychiatric Disorders. Microarrays (Basel). 2016; 5(1). PMC: 4795482. DOI: 10.3390/microarrays5010006. View

15.

Sun K, Gao Y, Wu H, Huang X . The causal relationship between gut microbiota and type 2 diabetes: a two-sample Mendelian randomized study. Front Public Health. 2023; 11:1255059. PMC: 10556527. DOI: 10.3389/fpubh.2023.1255059. View

16.

Wang C, Zhu D, Zhang D, Zuo X, Yao L, Liu T . Causal role of immune cells in schizophrenia: Mendelian randomization (MR) study. BMC Psychiatry. 2023; 23(1):590. PMC: 10428653. DOI: 10.1186/s12888-023-05081-4. View

17.

Li H, Hong W, Zhang C, Wu Z, Wang Z, Yuan C . IL-23 and TGF-β1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. J Affect Disord. 2014; 174:361-6. DOI: 10.1016/j.jad.2014.12.033. View

18.

Gordovez F, McMahon F . The genetics of bipolar disorder. Mol Psychiatry. 2020; 25(3):544-559. DOI: 10.1038/s41380-019-0634-7. View

19.

Burgess S, Bowden J, Fall T, Ingelsson E, Thompson S . Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. Epidemiology. 2016; 28(1):30-42. PMC: 5133381. DOI: 10.1097/EDE.0000000000000559. View

20.

Voelker R . What Is Bipolar Disorder?. JAMA. 2024; 331(10):894. DOI: 10.1001/jama.2023.24844. View